Home

Todd Foley

CIK 1473930 · last filed 2026-01-14

Todd Foley is a corporate insider who has filed 67 SEC Form 4 insider transactions across 11 companies since 2010. The most recent filing, for AKTS, was dated Jan 14, 2026. Across all open-market trades the lifetime net is −$124.1M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $220.3M across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$220.31M

Companies

11

Total Filings

67

Lifetime Open-Market Net

-$124.13M

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
AKTS Director 4,002,533 $24.21 $96.90M $4.19M 1 2026-01-14
Repare Therapeutics Inc. (RPTX) Delisted Director 2,268,195 $2.65 $6.01M -$17.12M 17 2023-06-12
TRDA Director 4,425,784 $6.08 $26.91M $2.00M 3 2022-06-06
iTeos Therapeutics, Inc. (ITOS) Delisted 10%+ Owner 3,041,865 $10.15 $30.87M -$61.38M 4 2021-11-24
CHIASMA, INC (CHMA) Delisted Director 10,426 $3.76 $39.2K $0 7 2021-08-05
RYTM Director 909,258 $106.13 $96.50M -$48.86M 26 2021-03-16
Harpoon Therapeutics, Inc. (HARP) Delisted 10%+ Owner 389,842 $23.01 $8.97M -$21.85M 1 2021-02-04
Oncorus, Inc. (ONCR) Delisted 10%+ Owner 2,675,677 $0.12 $322.6K $18.25M 1 2020-10-08
ARATANA THERAPEUTICS, INC. (PETX) Delisted 10%+ Owner 3,351,048 — — -$250.2K 2 2014-03-11
Eiger BioPharmaceuticals, Inc. (CLDN) Delisted Director 62,920 — — $892.9K 1 2014-02-06
EPIRUS Biopharmaceuticals, Inc. (CRXX) Delisted Director — — — $0 1 2010-01-20

Recent Filings

67 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-01-14 AKTS Mixed +4,235,403 $4.19M EDGAR
2023-06-12 Repare Therapeutics Inc. (RPTX) Delisted Grant (A) — $0 EDGAR
2022-06-06 TRDA Grant (A) — $0 EDGAR
2022-05-16 Repare Therapeutics Inc. (RPTX) Delisted Grant (A) — $0 EDGAR
2021-11-24 iTeos Therapeutics, Inc. (ITOS) Delisted Mixed −838,134 -$25.52M EDGAR
2021-11-04 TRDA Mixed +4,425,784 $2.00M EDGAR
2021-11-01 TRDA Grant (A) — $0 EDGAR
2021-09-27 iTeos Therapeutics, Inc. (ITOS) Delisted Sell (S) −481,212 -$13.36M EDGAR
2021-09-16 iTeos Therapeutics, Inc. (ITOS) Delisted Sell (S) −410,985 -$11.38M EDGAR
2021-09-08 iTeos Therapeutics, Inc. (ITOS) Delisted Mixed −665,154 -$11.12M EDGAR
Showing 1–10 of 67
Page 1 of 7
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.